3
Clinical Trials associated with Influenza vaccine (Split virion) / SuspendedEarly Phase 1IIT Exploratory study on the 2-dose immunization schedule of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent on children aged 3 to 8 years old in China
Start Date01 Aug 2021 |
Sponsor / Collaborator- |
[Translation] Clinical trials on the safety and immunogenicity of influenza virus split vaccines
通过2剂免疫后4周的抗体阳转率证明流感病毒裂解疫苗(0.25ml/支)在6月-35月龄岁人群中的免疫原性非劣效于对照疫苗(非劣效界值:≤10%)。
[Translation] The antibody positivity rate 4 weeks after 2 doses of immunization demonstrated that the immunogenicity of influenza virus split vaccine (0.25ml/dose) in people aged 6-35 months was non-inferior to the control vaccine (non-inferiority margin: ≤10%).
An Open Label, Phase-III Study to Evaluate the Safety and Immunogenicity of Influenza Vaccine (Split) of Changhchunchangsheng Life Sciences Ltd. In Pediatrics, Adolescent and Healthy Adults.? - Influenza (Split)
100 Clinical Results associated with Influenza vaccine (Split virion)
100 Translational Medicine associated with Influenza vaccine (Split virion)
100 Patents (Medical) associated with Influenza vaccine (Split virion)
100 Deals associated with Influenza vaccine (Split virion)